



3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

Product Information

ANTI-MATRIX METALLOPROTEINASE-17 (MMP-17, MT4-MMP), N-Terminal

Developed in Rabbit, Affinity Isolated Antibody

Product Number **M 3684**

Product Description

Anti-Matrix Metalloproteinase-17 (MMP-17, MT4-MMP) is developed in rabbit using a synthetic peptide corresponding to the N-terminal of human MMP-17 (membrane-type) as immunogen. Affinity isolated antigen specific antibody is obtained from rabbit anti-MMP-17 antiserum by immuno-specific purification which removes essentially all rabbit serum proteins, including immunoglobulins, which do not specifically bind to the peptide.

Rabbit Anti-MMP-17, N-Terminal may be used for the detection and localization of MMP-17 by various immunochemical techniques including immunoblotting, immunoprecipitation, immunohistochemistry, cell sorting, and ELISA.

Rabbit Anti-MMP-17, N-Terminal specifically binds to MMP-17 (MT4-MMP) and does not cross-react with the other MMP family members (MMP-1, MMP-2, MMP-3, MMP-9, etc). The zymogen for MMP-17 is approximately 65 kDa and is quickly activated to the 63 kDa form, which breaks down to a cascade of active forms. Anti-MMP-17, N-terminal recognizes the pro-form and active forms of MMP-17, as well as further activation/breakdown products. By immunoblotting against the reduced protein, the antibody reacts with bands at 65 kDa (proenzyme), 63 kDa (active), and a series of further cleaved active forms. Anti-MMP-17, N-terminal also recognizes non-reduced MMP-17.

The matrix metalloproteinases (MMPs) are a family of at least eighteen secreted and membrane-bound zinc-endopeptidases. Collectively, these enzymes can degrade all the components of the extracellular matrix, including fibrillar and non-fibrillar collagens, fibronectin, laminin and basement membrane glycoproteins.

In general, a signal peptide, a propeptide, and a catalytic domain containing the highly conserved zinc-binding site characterizes the structure of the MMPs. In addition, fibronectin-like repeats, a hinge region, and a C-terminal hemopexin-like domain allow categorization of MMPs into the collagenase, gelatinase, stomelysin and membrane-type MMP subfamilies.¹⁻³ MMPs contain the motif His-Glu-X-X-His (X represents any amino acid) that binds zinc in the catalytic site, as well as another zinc molecule and two calcium molecules structurally. They fall within the matrixin subfamily and are EC designated 3.4.24.x. This group also contains astacin, reprolysin, and serralyisin, as well as other more divergent metalloproteinases. All MMPs are synthesized as proenzymes, and most of them are secreted from the cells as proenzymes. Thus, the activation of these proenzymes is a critical step that leads to extracellular matrix breakdown.

MMPs are considered to play an important role in wound healing, apoptosis, bone elongation, embryo development, uterine involution, angiogenesis,⁴ and tissue remodeling, and in diseases such as multiple sclerosis,^{2,5} Alzheimer's,² malignant gliomas,² lupus, arthritis, periodontitis, glomerulonephritis, atherosclerosis, tissue ulceration, and in cancer cell invasion and metastasis.⁶ Numerous studies have shown that there is a close association between expression of various members of the MMP family by tumors and their proliferative and invasive behavior and metastatic potential.

The tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring proteins that specifically inhibit matrix metalloproteinases and regulate extracellular matrix turnover and tissue remodeling by forming tight-binding inhibitory complexes with the MMPs. Thus,

TIMPs maintain the balance between matrix destruction and formation. An imbalance between MMPs and the associated TIMPs may play a significant role in the invasive phenotype of malignant tumors. MMPs and TIMPs can be divided into two groups with respect to gene expression: the majority exhibit inducible expression and a small number are produced constitutively or are expressed at very low levels and are not inducible. Among agents that induce MMP and TIMP production are the inflammatory cytokines TNF- α and IL-1 β . A marked cell type specificity is a hallmark of both MMP and TIMP gene expression (i.e., a limited number of cell types can be induced to make these proteins).

Matrix Metalloproteinase-17 (MMP-17) is also known as membrane-type matrix metalloproteinase-4 (MT4-MMP). The human cDNA of MMP-17 was originally isolated from a human breast carcinoma cell line.^{7,8} MMP-17 has the least degree of sequence identity (less than 40 % in the catalytic domain) to the other MT-MMP family members. This protein has a putative transmembrane domain located at the end of the C-terminus; thus, it lacks a cytoplasmic tail that the other MT-MMPs contain.⁹ Its C-terminal sequence suggests that MMP-17 is a glycosylphosphatidylinositol (GPI) anchored proteinase.⁹

In addition to being present in breast cancers, MMP-17 is found highly expressed in brain, colon, ovary, and testis tissues as well as in leukocytes. The expression of MMP-17 (MT4-MMP) in leukocytes suggest that this enzyme could be involved in the activation of membrane-bound precursors of growth factors and inflammatory mediators such as TNF α .⁸ The expression of MMP-17 in breast tumors suggests a potential role for human MMP-17 in the tumoral process.⁸ The human MMP-17 gene has the chromosomal location of 12q24.3.^{10,11}

Reagent

Rabbit Anti-MMP-17, N-Terminal is supplied in 0.01 M phosphate buffered saline, pH 7.4, containing 50 % glycerol and 0.1 % sodium azide. The protein concentration is approximately 1 mg/ml.

Precautions and Disclaimer

Due to the sodium azide content a material safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2 °C to 8 °C for up to six months. For extended storage, the solution may be stored 0 °C to -20 °C. The antibody is supplied with 50 % glycerol to prevent freezing. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

Product Profile

A working dilution of 1:2,000 is determined by immunoblotting using a concentrated cell culture media from a stimulated human breast cancer cell line, an alkaline phosphatase conjugated secondary antibody and BCIP/NBT as the substrate. Higher antibody concentrations may be necessary for non-human samples.

Note: MMP-17 has been reported to be elevated in several tumor cell lines and is thought to be produced by some normal cell lines. Treatment of cells with concanavalin-A or the phorbol ester TPA stimulates production of MMP-17 (MT4-MMP) in some cell types. The enzyme can be recovered in cell lysates.

In order to obtain best results and assay sensitivity in different techniques and preparations we recommend determining optimum working dilutions by titration assay.

References

1. Borkakoti, N., Matrix metalloproteases: variations on a theme. *Prog. Biophys. Mol. Biol.*, **70**, 73-94 (1998).
2. Yong, V.W., et al., Matrix metalloproteinases and diseases of the CNS. *Trends in Neuroscience*, **21**, 75-80 (1998).
3. Kähäri, V.M., and Saarialho-Kere, U., Matrix metalloproteinases in skin. *Exp. Dermatol.*, **6**, 199-213 (1997).

4. Halpert, I., et al., Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. *Proc. Natl. Acad. Sci., USA*, **93**, 9748-9753 (1996).
5. Chandler, S., et al., Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. *J. Neuroimmunol.*, **72**, 155-161 (1997).
6. Birkedal-Hansen, H., et al., Matrix metalloproteinases: a review. *Crit. Rev. Oral. Biol. Med.*, **4**, 197-250 (1993).
7. Wang, Y., et al., Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. *J. Biol. Chem.*, **274**, 33043-33049 (1999).
8. Puente, X.S., et al., Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. *Cancer Res.*, **56**, 944-949 (1996).
9. Itoh, Y., et al., Membrane type 4 matrix metalloproteinase (MT4-MMP), MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. *J. Biol. Chem.*, **274**, 34260-34266 (1999).
10. Puente, X.S., et al., Localization of the human membrane type 4-matrix metalloproteinase gene (MMP17) to chromosome 12q24. *Genomics*, **54**, 578-579 (1998).
11. Kinoh, H., et al., Assignment of the genes for membrane-type-4 matrix metalloproteinase (Mmp17, MMP17) to mouse chromosome 5, human chromosome band 12q24.3 and membrane-type-5 matrix metalloproteinase (Mmp24, MMP24) to mouse chromosome 2 and human chromosome band 20q11.2-->q12, respectively, by radiation hybrid and in situ hybridization. *Cytogenet. Cell Genet.*, **87**, 97-98 (1999).

kaa 10/00

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.